WAS - Competitive Landscape and Market Insight, 2018

October 2018 | 54 pages | ID: W4E3030A2D8EN
DelveInsight

Abstracts

This report can be delivered to the clients within 24 hours

'Wiskott Aldrich syndrome - Competitive Landscape and Market Insight, 2018', report provides comprehensive Insight about pipeline drugs along with technologies involved across this indication. The report provides the detailed analysis of marketed as well as pipeline products along with the companies involved. The report covers the Market Scenario till 2027, Attribute analysis, Product Potential Analysis, Wiskott Aldrich syndrome Market Evolution, and Unmet Needs. This report further provides comprehensive Insight about the pipeline drugs. It covers all the clinical pipeline drug profiles and their comparative analysis along with forecasted sales for upcoming launches.

Products covered by Phase

• Phase III and Phase II

Overview of pipeline development activities for Wiskott Aldrich syndrome

Pipeline analysis of the therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

METHODOLOGY

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SCOPE

• The report provides competitive pipeline landscape of Wiskott Aldrich syndrome
• The report provides the marketed drugs information including its sales, development activities and details of patent expiry
• The report provides the insight of current and future market for Wiskott Aldrich syndrome
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Wiskott Aldrich syndrome pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Wiskott Aldrich syndrome and also provide company profiling
• Pipeline products coverage based on various stages of development ranging from late stage till mid stage
• Provides attribute analysis Report also covers the Attribute analysis, Product Potential Analysis, Wiskott Aldrich syndrome Market Evolution, Market Scenario, and Unmet Needs

REASONS TO BUY

• Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
• Establish a comprehensive understanding of the current pipeline scenario across Wiskott Aldrich syndrome to formulate effective R&D strategies
• Assess challenges and opportunities that influence Wiskott Aldrich syndrome R&D
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Devise corrective measures for pipeline projects by understanding Wiskott Aldrich syndrome pipeline depth and focus of Indication therapeutics
• Developing strategic initiatives to support your drug development activities
• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Wiskott Aldrich syndrome to enhance and expand business potential and scope
• Provides strategically significant competitor information, analysis, and Insight to formulate effective R&D development strategies
• Gaining a full picture of the Competitive Landscape for Evidence based Decisions

Contents

Introduction
Executive Summary
Wiskott-Aldrich Syndrome (WAS)
Overview
Clinical Features
Pathophysiology
Signs and Symptoms
Diagnosis
Treatment
Epidemiology Overview - 7MM, 2015-2027
Prevalence of Wiskott-Aldrich Syndrome in 7MM
Epidemiology of Wiskott-Aldrich Syndrome in 7 MM
Assumptions and Rationale
Prevalent Population of Wiskott-Aldrich Syndrome in 7MM
Incident Population of Wiskott-Aldrich Syndrome in 7MM
Competitive Landscape
Pipeline Scenario
Late Stage Products (Phase III)
Comparative Analysis
GSK2696275: GlaxoSmithKline
Product Description
Research and Development
Heat Map
Product Development Activities
GSK2696275, 7MM Forecasted Sales
GSK2696275 – Analyst Insight
Mid-Stage Products
Comparative Analysis
Market Assessment
Wiskott-Aldrich Syndrome – Share Evolution

7MM MARKET SIZE OF WISKOTT-ALDRICH SYNDROME

Historical & Forecasted Market Size
Attribute Analysis
Analysis
Potential Matrix
Analysis
Unmet Need
Appendix

List Of Tables

LIST OF TABLES

Table 1: Late Stage Products (Phase III)
Table 2: GSK2696275 Forecasted Sales (2020-2027)
Table 3: Mid Stage Products (Phase II)
Table 4: Drug 2 Forecasted Sales (2020-2027)
Table 5: Drug 3 Forecasted Sales (2021-2027)
Table 6: 7MM, Historical & Forecasted Prevalent Cases, 2015-2027
Table 7: 7MM, Historical & Forecasted Incident Cases, 2015-2027
Table 8: 7MM, Historical & Forecasted Market Size of Wiskott-Aldrich Syndrome, 2015-2027

List Of Figures

LIST OF FIGURES

Figure 1: Chromosomal Representation of Wiskott-Aldrich Syndrome protein (WASp)
Figure 2: Late Stage Products (Phase III)
Figure 3: GSK2696275 Forecasted Sales (2020-2027)
Figure 4: Mid Stage Products (Phase II)
Figure 5: Drug 2 Forecasted Sales (2020-2027)
Figure 6: Drug 3 Forecasted Sales (2021-2027)
Figure 7: 7MM, Historical & Forecasted Prevalent Cases, 2015-2027
Figure 8: 7MM, Historical & Forecasted Incident Cases, 2015-2027
Figure 9: 7MM, Historical & Forecasted Market Size of Wiskott-Aldrich Syndrome, 2015-2027